Clin2
NCT06694363Possibly a fitRecruiting

New test to guide treatment for APDS immune disorder

Activated PI3K Delta Syndrome

Treatments studied

Part of Immune system & allergy clinical trials.

This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
14 people
Ages
12 years and older
Study type
Observational

Who can take part

  • You are 12 years old or older
  • You have a confirmed diagnosis of APDS type 1 or type 2 (or have a new genetic change linked to APDS)
  • You have not had a bone marrow transplant
  • You are willing to provide blood samples for testing

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06990529Recruiting· Phase 2
Long-term safety and effectiveness of leniolisib for immune problems

This study tests the long-term safety and effectiveness of the drug leniolisib for people with certain immune system disorders. It is for people who have already been in a previous study of this drug and may benefit from continuing treatment.

Bethesda, Maryland
NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders

This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.

Paris
NCT06371417Recruiting· Phase 1
Testing RAY121 for several immune diseases (RAINBOW trial)

This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.

Orange, California
NCT06789913Recruiting· Phase 2
Testing RLY-2608 for growth disorders linked to PIK3CA mutations

This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.

Phoenix, Arizona
NCT07261891Recruiting
Lab study of JAK-STAT related disorders

This study looks at blood or tissue samples from people with certain genetic disorders that affect a key cell communication pathway (JAK-STAT). The goal is to learn more about these disorders and test potential treatments in the lab.

Leuven, Vlaams-Brabant
NCT02257892Recruiting
Study of rare immune system genetic disorders

This study looks for genetic causes of immune problems, such as unusually frequent infections, abnormal allergies, or autoimmune or inflammation conditions. It may help by improving how doctors understand these disorders and by matching families with possible genetic diagnoses.

Bethesda, Maryland

Hear when a new Activated PI3K Delta Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.